Patient cohort and conditioning regimens
| Sample . | Type of BMT . | Conditioning . | Days P-TX . | Donor cells, % of total . | Donor cells, % of microglia . |
|---|---|---|---|---|---|
| B1 | Myeloablative TBI | CY, TBI (13.2 Gy) | 514 | 0.61 | 5.08 |
| B2 | Myeloablative TBI | CY, TBI (12 Gy) | 500 | 0.5 | 4.17 |
| B3 | Myeloablative TBI | CY, TBI (10 Gy) | 194 | 1.79 | 14.92 |
| B4 | Myeloablative TBI | CY, FLU, TBI (15.7 Gy) | 161 | 0.85 | 7.08 |
| B5 | Myeloablative TBI | CY, TBI (12 Gy) | 157 | 0.72 | 6.0 |
| B6 | Myeloablative TBI | CY, FLU, TBI (12 Gy) | 107 | 1.44 | 12.0 |
| B7 | Myeloablative TBI | CY, FLU, TBI (12 Gy) | 102 | 1.1 | 9.17 |
| B8 | Myeloablative TBI | TEPA, FLU, TBI (13.2 Gy) | 79 | 0.72 | 6.00 |
| B9 | Myeloablative Cy | CY (X4) | 208 | 0.92 | 7.67 |
| B10 | Myeloablative Bu | BU, CY, ATG | 262 | 0.79 | 6.58 |
| B11 | Myeloablative Treo | FLU, TREO | 85 | 0.53 | 4.42 |
| B12 | Myeloablative Bu | BU, FLU, ATG | 76 | 1.0 | 8.33 |
| B13 | Nonmyeloablative | FLU, TBI (3 Gy) | 178 | 0.16 | 1.33 |
| B14 | Nonmyeloablative | CY, FLU, TBI (2 Gy) | 143 | 0.14 | 1.17 |
| B15 | Nonmyeloablative | FLU, TBI (3 Gy) | 44 | 0.16 | 1.33 |
| Sample . | Type of BMT . | Conditioning . | Days P-TX . | Donor cells, % of total . | Donor cells, % of microglia . |
|---|---|---|---|---|---|
| B1 | Myeloablative TBI | CY, TBI (13.2 Gy) | 514 | 0.61 | 5.08 |
| B2 | Myeloablative TBI | CY, TBI (12 Gy) | 500 | 0.5 | 4.17 |
| B3 | Myeloablative TBI | CY, TBI (10 Gy) | 194 | 1.79 | 14.92 |
| B4 | Myeloablative TBI | CY, FLU, TBI (15.7 Gy) | 161 | 0.85 | 7.08 |
| B5 | Myeloablative TBI | CY, TBI (12 Gy) | 157 | 0.72 | 6.0 |
| B6 | Myeloablative TBI | CY, FLU, TBI (12 Gy) | 107 | 1.44 | 12.0 |
| B7 | Myeloablative TBI | CY, FLU, TBI (12 Gy) | 102 | 1.1 | 9.17 |
| B8 | Myeloablative TBI | TEPA, FLU, TBI (13.2 Gy) | 79 | 0.72 | 6.00 |
| B9 | Myeloablative Cy | CY (X4) | 208 | 0.92 | 7.67 |
| B10 | Myeloablative Bu | BU, CY, ATG | 262 | 0.79 | 6.58 |
| B11 | Myeloablative Treo | FLU, TREO | 85 | 0.53 | 4.42 |
| B12 | Myeloablative Bu | BU, FLU, ATG | 76 | 1.0 | 8.33 |
| B13 | Nonmyeloablative | FLU, TBI (3 Gy) | 178 | 0.16 | 1.33 |
| B14 | Nonmyeloablative | CY, FLU, TBI (2 Gy) | 143 | 0.14 | 1.17 |
| B15 | Nonmyeloablative | FLU, TBI (3 Gy) | 44 | 0.16 | 1.33 |
| Sample . | First HSCT . | Second HSCT . | Donor cells . | |||
|---|---|---|---|---|---|---|
| Conditioning . | Days-P-Tx . | Conditioning . | Days-P-Tx . | % Total . | % Microglia . | |
| B16 | CY, TBI (10 Gy) | 629 | No Conditioning | 42 | 1.59 | 13.25 |
| B17 | CY, TBI (12 Gy), MTX | 398 | BU, CY | 24 | 1.47 | 12.26 |
| B18 | CY, TBI | 5690 | TREO, FLU | 10 | 3.01 | 25.07 |
| B19 | BU, CY | 1716 | FLU, CY TBI | 61 | 1.76 | 14.66 |
| Sample . | First HSCT . | Second HSCT . | Donor cells . | |||
|---|---|---|---|---|---|---|
| Conditioning . | Days-P-Tx . | Conditioning . | Days-P-Tx . | % Total . | % Microglia . | |
| B16 | CY, TBI (10 Gy) | 629 | No Conditioning | 42 | 1.59 | 13.25 |
| B17 | CY, TBI (12 Gy), MTX | 398 | BU, CY | 24 | 1.47 | 12.26 |
| B18 | CY, TBI | 5690 | TREO, FLU | 10 | 3.01 | 25.07 |
| B19 | BU, CY | 1716 | FLU, CY TBI | 61 | 1.76 | 14.66 |
Cerebral cortical biopsies were obtained from 19 female patients who underwent sex-mismatched stem cell transplantation. Cases were selected based on availability, conditioning regimen, posttransplantation survival, and number of stem cell transplantations.
From B1 to B8, patients conditioned with TBI-based myeloablation (10-15.7 Gy); B9, patients treated with high-dose (4X) cytarabine myeloablation; from B10 to 12, patients conditioned with busulfan or treosulfan-based myeloablation; from B13 to 15, patients conditioned with TBI-based nonmyeloablation; and from B16 to 19, patients who received 2 separate stem cell transplantations.
Donor cells are reported as percent total cellularity (donor cells % of total) and percentage of microglia cells (donor cell % of microglia).
ATG, antithymocyte globulin; BU, busulfan; CY, cytarabine; Days PTx, posttransplantation survival listed as days after transplantation; FLU, fludarabine; MTX, methotrexate; TREO, treosulfan; TEPA, thiotepa.